BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 38637495)

  • 1. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
    Cheng B; Li C; Li J; Gong L; Liang P; Chen Y; Zhan S; Xiong S; Zhong R; Liang H; Feng Y; Wang R; Wang H; Zheng H; Liu J; Zhou C; Shao W; Qiu Y; Sun J; Xie Z; Liang Z; Yang C; Cai X; Su C; Wang W; He J; Liang W
    Signal Transduct Target Ther; 2024 Apr; 9(1):93. PubMed ID: 38637495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
    Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
    Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer.
    Guo W; Zhou B; Bie F; Huai Q; Xue X; Guo L; Tan F; Xue Q; Zhao L; Gao S
    Clin Transl Med; 2023 Oct; 13(10):e1453. PubMed ID: 37846760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study.
    Zhao ZR; Lin ZC; Shen JF; Xie ZH; Jiang L
    Ann Thorac Surg; 2023 Oct; 116(4):703-710. PubMed ID: 36521526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer.
    Xu L; Shi M; Wang S; Li M; Yin W; Zhang J; Zhu J; Jiang F; Xia W; Qiu N; Zhang Z; Huang J; Ma Z; Meng F; Zhu H; Dong G; Wang J; Yin R
    Front Immunol; 2022; 13():1009621. PubMed ID: 36389707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.
    Qu R; Ye F; Hu S; Wang B; Qin S; Xiong J; Fu X; Li L; Cai Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3775-3788. PubMed ID: 35986758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
    Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
    Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV; Housley F; Yau C; Nakagawa R; Winkler J; Anttila JM; Munne PM; Savelius M; Houlahan KE; Van de Mark D; Hemmati G; Hernandez GA; Zhang Y; Samson S; Baas C; Kok M; Esserman LJ; van 't Veer LJ; Rugo HS; Curtis C; Klefström J; Matloubian M; Goga A
    Nat Commun; 2022 Jun; 13(1):3671. PubMed ID: 35760778
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.